A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
In the laboratory, Kevetrin activates p53, a tumor suppressor protein that has an important
role in protecting the body. p53 functions by activating proteins that repair DNA and kill
cells that have genetic mutations such as in cancers. Research experiments showed that when
cancer cells were treated with Kevetrin, it activated p53 which induced p21, a protein that
inhibits cancer cell growth. p53 also induced PUMA (p53 up-regulated modulator of apoptosis),
a protein that causes tumor cell death. Because of these activities, slowing cancer cell
growth and causing cancer cell death, Kevetrin may help to treat tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Cellceutix Corporation
Collaborators:
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute